Session Abstract – PMWC 2022 Silicon Valley
The diagnosis, risk stratification, and treatment of cancer have become increasingly personalized. Clinicians utilize novel testing technologies to select targeted therapeutics based on predictive biomarkers. The advent of newer and less invasive approaches to diagnosis such as liquid biopsy is enabling clinicians to better tailor treatment plans for their patients. Novel immunotherapy agents used alone or in combination with other agents may further optimize outcomes for patients with advanced disease. This session will explore the unique challenges that community-based clinicians face in their practice.
Session Chair Profile
M.D., Director Field Medical Oncology, Foundation Medicine
Biography
Jerry Mitchell has a current focus on national education and support for oncologists around comprehensive genomic profiling with an attention to therapeutic applications. Prior to joining Foundation Medicine he was a practicing oncologist at the Mark H. Zangmeister Center in Columbus, OH. He is Board Certified in Internal Medicine, Oncology, Hematology, and Hospice and Palliative Care. He received his MD from the University of North Carolina at Chapel Hill and his MBA from the Kelley School of Business at Indiana University with an emphasis on corporate strategy.
Speaker Profile
Research Advocate/Patient Advocate, UCSF Breast Science Advocacy Core
Biography
Over 30 years of experience in life science consulting, investment and portfolio management, advising biotech, pharma, diagnostics and device companies, investment firms, universities and government agencies worldwide. Co-founder, venture partner and key person of Global Biomedical Partners, managing International Biomedicine Holdings, a $400 million fund based in Basel, Switzerland. Former member of Board of Directors of Innodia, Inc. and Board observer of Syntonix Pharmaceuticals. Business analyst in the corporate venture capital office of WR Grace & Co. A breast cancer survivor since 2000, Vivian applies her personal experience as a patient and professional experience as a life science industry consultant to her cancer advocacy work. Vivian collaborates with research investigators at academic institutions across the US and abroad to provide patient perspective in shaping grant applications to, and research projects funded by, US Department of Defense (DoD), California Breast Cancer Research Program (CBCRP), Susan G. Komen, Sidney Kimmel Foundation, American Society of Clinical Oncology (ASCO)’s Conquer Cancer Foundation and Patient-Centered Outcomes Research Institute (PCORI). She is an Advocate Advisor to the University of California’s Athena Breast Health Network, providing patient input for its WISDOM Study on personalized breast cancer screening, for which Athena has been awarded a $14 million Pragmatic Clinical Studies grant by PCORI. Vivian has served as a Consumer Reviewer for the DoD Breast Cancer Research Program, and as a Peer Reviewer for Komen grants on the national and local levels. She has served as an Advocate Observer on the California Breast Cancer Research Program (CBCRP) Community Impact Review Panel. Vivian serves on the Volunteer Leadership Council of the American Cancer Society’s California Chinese Unit and is a member of Bay Area Young Survivors (BAYS), mentoring newly diagnosed patients. Vivian is a member of Komen’s Advocate In Sciences program and a graduate of National Breast Cancer Coalition’s Project LEAD Institute as well as Research Advocacy Network’s Focus on Science scholar program. She earned her Bachelor’s degree in Biochemistry from Harvard University and conducted research in the Tumor Immunology department of Dana Farber Cancer Center.
Speaker Profile
Chief WayFinder, One Cancer Place
Biography
Erika is the Designer/Builder/Leader of ONE CANCER PLACE - the Cancer Learning Community. ONE CANCER PLACE is the new destination for a new way of understanding cancer. Our PASSION is for the implementation of universal biomarker testing for all cancer patients at first-line treatment, regardless of staging.
Speaker Profile
M.D., Ph.D., Chief Medical Director Clinical Trial & Operations Medical Director, AFCAC, Sutter Health
Biography
Christopher Woods, MD PhD is a cardiac electrophysiologist with a particular focus on both atrial fibrillation and complex ventricular tachycardia. He serves as Chief Medical Director of Clinical Trial Operations for the Sutter Health Research Enterprise, and Medical Director of the Atrial Fibrillation and Complex Arrhythmia Center (AFCAC) at Sutter Health’s Mills-Peninsula Medical Center and California Pacific Medical Center. Dr. Woods’ research focuses on translational cardiovascular diseases. He investigates novel therapies for supraventricular tachycardia, atrial fibrillation, and ventricular tachycardia, as well as stroke prevention. These include investigator-initiated and industry-supported clinical trials in the focus areas described above. Dr. Woods received an M.D. and Ph.D. from the University of California at Los Angeles through the NIH Medical Scientist Training Program. He completed residency training in internal medicine at Stanford University as part of the clinical investigator pathway, fellowship and chief fellowship in cardiology also at Stanford, and clinical cardiac electrophysiology fellowship at the University of California at San Francisco.
